TY - JOUR
T1 - Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients
T2 - is there a best sequence?
AU - Rossi, Lorenzo
AU - McCartney, Amelia
AU - Risi, Emanuela
AU - Malorni, Luca
AU - Biganzoli, Laura
AU - Di Leo, Angelo
N1 - Funding Information:
Angelo Di Leo is a consultant for Pfizer, Novartis and Lilly. Luca Malorni is a consultant for Pfizer, Astra Zeneca, Novartis and a grant recipient of Pfizer. Other authors have nothing to disclose.
Publisher Copyright:
© The Author(s), 2018.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - The current therapeutic landscape of luminal human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC) is fundamentally evolving, particularly in the advent of molecularly targeted therapies, such as inhibitors of mammalian target of rapamycin and cyclin-dependent kinase 4/6 (CDK4/6). In the context of CDK4/6 inhibitors, landmark clinical trials for palbociclib (PALOMA-1, PALOMA-2, PALOMA-3), ribociclib (MONALEESA-2, MONALEESA-3, MONALEESA-7) and abemaciclib (MONARCH-1, MONARCH-2, MONARCH-3) have provided solid data regarding progression-free survival and overall response rate, justifying the introduction of this class of drugs into our therapeutic armoury. However, several clinical questions remain open. One of the most relevant issues faced in practice is that of the optimum sequencing of CDK4/6 inhibitors, particularly given the wide range of therapeutic options open to clinicians treating luminal mBC. In this brief commentary, we would like to focus on the best sequence for CDK4/6 inhibitors and their place in this growing, complex scenario.
AB - The current therapeutic landscape of luminal human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC) is fundamentally evolving, particularly in the advent of molecularly targeted therapies, such as inhibitors of mammalian target of rapamycin and cyclin-dependent kinase 4/6 (CDK4/6). In the context of CDK4/6 inhibitors, landmark clinical trials for palbociclib (PALOMA-1, PALOMA-2, PALOMA-3), ribociclib (MONALEESA-2, MONALEESA-3, MONALEESA-7) and abemaciclib (MONARCH-1, MONARCH-2, MONARCH-3) have provided solid data regarding progression-free survival and overall response rate, justifying the introduction of this class of drugs into our therapeutic armoury. However, several clinical questions remain open. One of the most relevant issues faced in practice is that of the optimum sequencing of CDK4/6 inhibitors, particularly given the wide range of therapeutic options open to clinicians treating luminal mBC. In this brief commentary, we would like to focus on the best sequence for CDK4/6 inhibitors and their place in this growing, complex scenario.
KW - abemaciclib
KW - best-sequence therapy
KW - CDK4/6 inhibitors
KW - metastatic breast cancer
KW - palbociclib
KW - ribociclib
UR - http://www.scopus.com/inward/record.url?scp=85058633126&partnerID=8YFLogxK
U2 - 10.1177/1758835918815591
DO - 10.1177/1758835918815591
M3 - Editorial
AN - SCOPUS:85058633126
SN - 1758-8340
VL - 10
SP - 1
EP - 5
JO - Therapeutic Advances in Medical Oncology
JF - Therapeutic Advances in Medical Oncology
ER -